FEB 27, 2019 6:45 PM PST

Are They Really Killer-T Cells?

WRITTEN BY: Nicholas Breehl

Scientists at the University of Virginia School of Medicine have discovered a defect in immune cells known as "killer T cells" that explains their inability to destroy cancer tumors. The researchers believe that repairing this defect could make the cells much better cancer killers. Further, they predict their discovery could be used within three to five years to help identify patients who will best respond to cancer therapies.

The finding could be a significant boost to the burgeoning field of immunotherapy, which aims to harness the body's immune defenses to defeat cancer. The discovery could also let doctors better predict and assess how well a patient responds to treatment.

"For a long time, the presence of immune cells in cancer has been associated with a better outcome in patients, but it's not been clear why the immune cells haven't been able to control the cancer. What is the cancer doing?" said researcher Timothy Bullock, Ph.D., of the UVA Cancer Center. "This [finding] gives us plenty of opportunities to come in with interventions to invigorate these T cells and level the playing field substantially, so they're much more competitive."

Building Better Cancer Killers

Despite their fearsome moniker, "killer" T cells often become inactive in solid tumors. UVA's new research sheds light on why. Bullock and his team determined that these sluggish soldiers suffer from a dysfunctional enzyme, enolase 1. Without it, they cannot use a vital nutrient, glucose.

"There is a functional defect in this enzyme that is preventing the cells from breaking down glucose and using it in such a way that they can proliferate and become functional," explained researcher Lelisa F. Gemta. "They don't process it well, and that's what we've been digging into: to find out why do these cells take up glucose but fail to break it down."

By ramping up the effectiveness of the enzyme, the researchers believe they can make the killer T cells much better at killing cancer. The sluggish soldiers would become much more formidable fighters.

The researchers also believe that doctors will be able to examine the enzyme to predict how well a patient will respond to treatment. "I think that there is an opportunity to actually use this enzyme as a read-out for the quality of the T cells that are in the tumor, so that when a physician comes in with a clinical trial, we can theoretically analyze how the T cells metabolically compare within the tumor," said Bullock, of UVA's Department of Pathology. "It's almost a biomarker of immune function and fitness within the tumors."

The research is part of UVA's aggressive efforts to advance the field of immunotherapy. For example, it is conducting a leading-edge clinical trial of experimental immunotherapy for pediatric acute lymphoblastic leukemia that has resisted other forms of treatment. The approach, known as chimeric antigen receptor T-cell therapy, takes a child's immune cells and genetically modifies them to make them better at killing cancer.

By confronting the defect, they have discovered and making these T cells fitter, Bullock hopes that his discovery will complement such emerging treatments and make them more effective. The finding, he notes, also might be put to use one day to dampen excessive immune responses, such as are seen in autoimmune disorders.

Sources: Science Daily, Science, YouTube

About the Author
You May Also Like
FEB 07, 2021
Microbiology
Positive Results From A Clinical Trial of an HIV Vaccine
FEB 07, 2021
Positive Results From A Clinical Trial of an HIV Vaccine
After years of effort, researchers are reporting that there were encouraging results from a phase 1 clinical trial which ...
FEB 18, 2021
Immunology
Protective COVID Antibodies Found in Breast Milk
FEB 18, 2021
Protective COVID Antibodies Found in Breast Milk
University of Rochester researchers analyzing breast milk samples from mothers with COVID-19 found that it doesn’t ...
MAR 31, 2021
Microbiology
Deep-Sea Microbes Are 'Invisible' to the Human Immune System
MAR 31, 2021
Deep-Sea Microbes Are 'Invisible' to the Human Immune System
Scientists took an exploratory journey to a place in the central Pacific Ocean in Kirbati called the Phoenix Islands Pro ...
APR 19, 2021
Cell & Molecular Biology
Insight Into the Molecular Basis of Rheumatoid Arthritis
APR 19, 2021
Insight Into the Molecular Basis of Rheumatoid Arthritis
New research has shown how variants in an immune gene can lead to a high risk of developing the autoimmune disorder rheu ...
MAY 23, 2021
Health & Medicine
Paronychia: What Is It and How Do You Treat It?
MAY 23, 2021
Paronychia: What Is It and How Do You Treat It?
It's one of the most common infections of the hand that nail biters are all too familiar with. Better known as a han ...
JUN 15, 2021
Clinical & Molecular DX
An Early Warning System for Type 1 Diabetes in Children
JUN 15, 2021
An Early Warning System for Type 1 Diabetes in Children
In type 1 diabetes, or T1D, the body’s own immune system mistakenly launches an aggressive attack on insulin-produ ...
Loading Comments...